Skip to content
    Real-World Studies

    Real-World Survival and Treatment Heterogeneity in Third-Line or Later DLBCL

    Wallington et alJournal of Clinical Medicine

    In diffuse large B-cell lymphoma (DLBCL), while standard of care is well established in the first-line setting, the introduction of multiple novel agents for relapsed or refractory disease has produced a highly heterogeneous real-world treatment landscape in third-line or later (3L+) settings. Evaluating outcomes in this population remains critical for bench-marking against clinical trials and external control arms.
    This retrospective, observational cohort study evaluated treatment patterns and real-world overall survival (rwOS) among patients receiving 3L+ therapy for DLBCL using an electronic health record dataset from COTA (now Verana Health). To facilitate robust comparisons with trial cohorts, eligibility was determined using a multiple index date qualification method, assessing patients at the initiation of each distinct 3L+ line of therapy (LOT) and analyzing rwOS using Kaplan–Meier methods.
    Among 476 unique patients identified, a total of 716 qualifying index-LOTs were analyzed. Documented Eastern Cooperative Oncology Group (ECOG) performance scores of 0 to 2 were present in 57% of qualifying-LOTs, while 43% were classified as missing or unknown. Median rwOS was 8.0 months (95% CI: 6.9, 10.6) across all qualifying-LOTs. Survival varied substantially based on the qualification approach, showing a median rwOS of 11.4 months (95% CI: 9.7, 13.6) at the first-qualifying LOT versus 6.3 months (95% CI: 5.3, 8.0) at the last-qualifying LOT. Notably, patients with missing or unknown ECOG status did not experience inferior survival relative to those with documented scores of 0 to 2.
    The authors concluded that observed rwOS figures closely mirror outcomes observed in comparator arms of contemporary clinical trials, highlighting a persistent unmet need for effective standard-of-care options in advanced R/R DLBCL. Furthermore, the divergence in survival outcomes depending on whether first-, last-, or all-qualifying index dates are utilized underscores that index date selection methodology is pivotal when constructing real-world comparator cohorts.

    Key Takeaways

    • Across 716 index lines of therapy in 476 patients with 3L+ diffuse large B-cell lymphoma, median real-world overall survival was 8.0 months (95% CI: 6.9–10.6) overall, ranging from 11.4 months (95% CI: 9.7–13.6) for first-qualifying to 6.3 months (95% CI: 5.3–8.0) for last-qualifying lines.
    • Patients with missing or unknown baseline ECOG performance scores (43% of qualifying lines of therapy) did not experience worse survival outcomes compared with those with documented scores of 0 to 2 (57%).
    Read the original sourceJournal of Clinical Medicine